BiotechTube

suprachoroidal CLS-TA + suprachoroidal sham + IVT aflibercept

Phase 3Terminated
0 watching 0 views this week๐Ÿ“ˆ Rising
69
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Macular Edema

Conditions

Macular Edema, Retinal Vein Occlusion

Trial Timeline

Jan 31, 2017 โ†’ Dec 10, 2018

NCT ID
NCT02980874

About suprachoroidal CLS-TA + suprachoroidal sham + IVT aflibercept

suprachoroidal CLS-TA + suprachoroidal sham + IVT aflibercept is a phase 3 stage product being developed by Clearside Biomedical for Macular Edema. The current trial status is terminated. This product is registered under clinical trial identifier NCT02980874. Target conditions include Macular Edema, Retinal Vein Occlusion.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02980874Phase 3Terminated

Competing Products

20 competing products in Macular Edema

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
44
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
33
4 mg CLS-TA + Sham + IVT afliberceptClearside BiomedicalPhase 2
44
suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or AvastinClearside BiomedicalPhase 3
69
CLS-AX + AfliberceptClearside BiomedicalPhase 2
44
Eylea + ALT-L9AlteogenPhase 1
33
KVD001 InjectionKalVista PharmaceuticalsPhase 2
47
KVD001 InjectionKalVista PharmaceuticalsPhase 1
28
FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
77
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
77
UBX1325 injection 50 ฮผL + EYLEAยฎ (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
44
UBX1325Unity BiotechnologyPhase 2
44
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
44
UBX1325Unity BiotechnologyPhase 1
25
CT-P42 + EyleaCelltrionPhase 3
77
Faricimab + AfliberceptChugai PharmaceuticalPhase 3
77
Faricimab + AfliberceptChugai PharmaceuticalPhase 3
77
DS-7080a + RanibizumabDaiichi SankyoPhase 1
33
Fovistaยฎ + bevacizumab + ranibizumab + afliberceptAstellas PharmaPhase 2
52
MA09-hRPEAstellas PharmaPre-clinical
23

Other Products from Clearside Biomedical

4 mg CLS-TA Suprachoriodal InjectionPhase 3
69
suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or AvastinPhase 3
69
4mg CLS-TA Suprachoriodal Injection + Sham ProcedurePhase 3
69
4 mg CLS-TA + Sham + IVT afliberceptPhase 2
44
CLS-AX + AfliberceptPhase 2
44